Closing a treatment gap current guidelines don't cover.
TARGET is a five-year clinical trial across Kenya and Tanzania testing whether two antibiotics reduce death and hospitalisation in children with acute watery diarrhoea and malnutrition — a group WHO guidance doesn't currently address.
Target tests two antibiotics, azithromycin and ciprofloxacin, against placebo in children aged 2 to 59 months who have acute watery diarrhoea and either stunting or wasting.
Earlier trial data suggest this group benefits most from treatment, yet WHO guidance doesn't currently recommend antibiotics for watery diarrhoea.
TARGET is built to close that evidence gap.
Earlier trial data suggest this group benefits most from treatment, yet WHO guidance doesn't currently recommend antibiotics for watery diarrhoea.
TARGET is built to close that evidence gap.
Our Research
What we're doing
Running the antibiotic trial
Enrolling 2,800 children across Kenya and Tanzania.
Finding who benefits most
Lab testing to identify which children gain the most from treatment.
Climate and resistance risk
Testing whether the findings hold in other settings, and studying how climate change could shift disease and antimicrobial resistance patterns.
Understanding care practices today
Mapping how diarrhoea is currently treated and by whom.
Turning evidence into policy
Translating trial results into guidance decision-makers can use.
Building local research community
Training the next generation of trial leaders in Kenya and Tanzania.
Partners
9 organisations, 3 continents
Follow the trial, and latest updates
.png)
Get Target updates twice a year. Subscribe to our newsletter.
